Utilization of an Automated Latex Agglutination Turbidity Assay for Assessing Gastric Mucosal Alteration during Helicobacter pylori Infection
5
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: A latex agglutination turbidity (LA) assay to test for serum antibodies has been approved in Japan and Korea for mass screening of Helicobacter pylori infection. In this study, we evaluated the LA assay for diagnosing H. pylori infection and predicting gastric mucosal changes in a Mongolian population. Methods: In total, 484 individuals were classified into H. pylori-positive (n=356) and H. pylori-negative (n=128) groups, as determined by histology and H. pylori culture. Results: The best cutoff, sensitivity, and specificity values for the LA assay were 18.35 U/mL, 74.2%, and 65.6%, respectively. The LA values in the atrophic gastritis group were statistically higher than those in the other groups (healthy, chronic gastritis, intestinal metaplasia, and gastric cancer, p<0.0001). The cutoff value to distinguish the atrophic gastritis group from the other four groups was 32.0 U/mL, and its area under the curve was 0.673, which was the highest among the E-plate, pepsinogen (PG) I, PG II, and PG I/II ratio tests in our data. The odds ratios for atrophic gastritis determined by the LA assay and PG I test in multiple logistic regression were 2.5 and 1.9, respectively, which were significantly higher than for the other tests. Conclusions: The LA assay can determine the risk of atrophic gastritis, which in turn is a considerable risk factor for gastric cancer. We propose using this assay in combination with the PG I/II ratio to avoid missing gastric cancer patients who have a low LA value (less than 32.0 U/mL).
Abstract
Background/Aims: A latex agglutination turbidity (LA) assay to test for serum antibodies has been approved in Japan and Korea for mass screening of Helicobacter pylori infection. In this study, we evaluated the LA assay for diagnosing H. pylori infection and predicting gastric mucosal changes in a Mongolian population. Methods: In total, 484 individuals were classified into H. pylori-positive (n=356) and H. pylori-negative (n=128) groups, as determined by histology and H. pylori culture. Results: The best cutoff, sensitivity, and specificity values for the LA assay were 18.35 U/mL, 74.2%, and 65.6%, respectively. The LA values in the atrophic gastritis group were statistically higher than those in the other groups (healthy, chronic gastritis, intestinal metaplasia, and gastric cancer, p<0.0001). The cutoff value to distinguish the atrophic gastritis group from the other four groups was 32.0 U/mL, and its area under the curve was 0.673, which was the highest among the E-plate, pepsinogen (PG) I, PG II, and PG I/II ratio tests in our data. The odds ratios for atrophic gastritis determined by the LA assay and PG I test in multiple logistic regression were 2.5 and 1.9, respectively, which were significantly higher than for the other tests. Conclusions: The LA assay can determine the risk of atrophic gastritis, which in turn is a considerable risk factor for gastric cancer. We propose using this assay in combination with the PG I/II ratio to avoid missing gastric cancer patients who have a low LA value (less than 32.0 U/mL).
참고문헌 (41)
- Schistosomes, "liver flukes and Helicobacter pylori", IARC Monogr Eval Carcinog Risks Hum, 61, pp.1~241 (1994)
- Marshall BJ, "Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration", Lancet, 1, pp.1311~1315 (1984)
- Olbe L, "Mechanisms involved in Helicobacter pylori induced duodenal ulcer disease : an overview", World J Gastroenterol, 6, pp.619~623 (2000)
- Forman D, "Association between infection with Helicobacter pylori and risk of gastric cancer : evidence from a prospective investigation", BMJ, 302, pp.1302~1305 (1991)
- Nomura A, "Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii", N Engl J Med, 325, pp.1132~1136 (1991)
- Parsonnet J, "Helicobacter pylori infection and the risk of gastric carcinoma", N Engl J Med, 325, pp.1127~1131 (1991)
- Wang RT, "Helicobacter pylori infection and gastric cancer : evidence from a retrospective cohort study and nested case-control study in China", World J Gastroenterol, 8, pp.1103~1107 (2002)
- Lauren P, "The two histological main types of gastric carcinoma : diffuse and so-called intestinal-type carcinoma : an attempt at a histo-clinical classification", Acta Pathol Microbiol Scand, 64, pp.31~49 (1965)
- Jekarl DW, "Evaluation of a newly developed rapid stool antigen test using an immunochromatographic assay to detect Helicobacter pylori", Jpn J Infect Dis, 66, pp.60~64 (2013)
- Kakiuchi T, "Evaluation of a novel stool antigen rapid test kit for detection of Helicobacter pylori infection", J Clin Microbiol, 57, pp.e01825~e01818 (2019)
- Kawai S, "Comparison of the detection of Helicobacter pylori infection by commercially available serological testing kits and the 13C-urea breath test", J Infect Chemother, 25, pp.769~773 (2019)
- Kodama M, "Evaluation of a novel anti-H. pylori antibody detection kit by latex turbidimetric immunoassay", Clin Lab, 65, pp.180918~ (2019)
- Casamayor M, "Targeted literature review of the global burden of gastric cancer", Ecancermedicalscience, 12, pp.883~ (2018)
- Kayali S, "Non-invasive tests for the diagnosis of helicobacter pylori : state of the art", Acta Biomed, 89(8-S), pp.58~64 (2018)
- Lu CY, "The best method of detecting prior Helicobacter pylori infection", World J Gastroenterol, 11, pp.5672~5676 (2005)
- Akada J, "Serum Helicobacter pylori antibody reactivity in seven Asian countries using an automated latex aggregation turbidity assay", J Gastroenterol Hepatol, 36, pp.2198~2209 (2021)
- Tsutsumi K, "Diagnostic accuracy of latex agglutination turbidimetric immunoassay in screening adolescents for Helicobacter pylori infection in Japan", Digestion, 98, pp.75~80 (2018)
- Skrebinska S, "Accuracy of two plasma antibody tests and faecal antigen test for non-invasive detection of H. pylori in middle-aged Caucasian general population sample", Scand J Gastroenterol, 53, pp.777~783 (2018)
- Baek SM, "Role of serum pepsinogen II and Helicobacter pylori status in the detection of diffusetype early gastric cancer in young individuals in South Korea", Gut Liver, 14, pp.439~449 (2020)
- Khasag O, "The prevalence of Helicobacter pylori infection and other risk factors among Mongolian dyspeptic patients who have a high incidence and mortality rate of gastric cancer", Gut Pathog, 10, pp.14~ (2018)
- "International Classification of Disease 11th Revision. Helicobacter pylori" (2021)[URL]
- Malfertheiner P, "Management of Helicobacter pylori infection : the Maastricht VI", Florence consensus report, 2022, pp.71, 1724~1762
- Park YH, "Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer", J Cancer Prev, 20, pp.25~40 (2015)
- Tatsuta M, "Fundal atrophic gastritis as a risk factor for gastric cancer", Int J Cancer, 53, pp.70~74 (1993)
- Leung WK, "Review article : intestinal metaplasia and gastric carcinogenesis", Aliment Pharmacol Ther, 16, pp.1209~1216 (2002)
- Gantuya B, "New observations regarding Helicobacter pylori and gastric cancer in Mongolia", Helicobacter, 23, pp.e12491~ (2018)
- Rotimi O, "Histological identification of Helicobacter pylori : comparison of staining methods", J Clin Pathol, 53, pp.756~759 (2000)
- Talebi Bezmin Abadi A, "Diagnosis of Helicobacter pylori using invasive and noninvasive approaches", J Pathog, 2018, pp.9064952~ (2018)
- Berlth F, "Pathohistological classification systems in gastric cancer : diagnostic relevance and prognostic value", World J Gastroenterol, 20, pp.5679~5684 (2014)
- Dixon MF, "Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994", Am J Surg Pathol, 20, pp.1161~1181 (1996)
- Toyoshima O, "Serum anti-Helicobacter pylori antibody titer and its association with gastric nodularity, atrophy, and age : a cross-sectional study", World J Gastroenterol, 24, pp.4061~4068 (2018)
- Gatta L, "Quantification of serum levels of pepsinogens and gastrin to assess eradication of Helicobacter pylori", Clin Gastroenterol Hepatol, 9, pp.440~442 (2011)
- Wagner S, "Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer : significance of inflammation and effect of bacterial eradication", Am J Gastroenterol, 89, pp.1211~1218 (1994)
- Miki K, "Gastric cancer screening using the serum pepsinogen test method", Gastric Cancer, 9, pp.245~253 (2006)
- Gantuya B, "Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area", Gastric Cancer, 22, pp.104~112 (2019)
- Di Mario F, "Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis : relationship with inflammation, activity, and density of the bacterium", Dig Dis Sci, 51, pp.1791~1795 (2006)
- Leja M, "The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard histopathology", Dig Dis Sci, 54, pp.2377~2384 (2009)
- Tokai Y, "Usefulness of the ltype Wako Helicobacter pylori antibody J test", JGH Open, 5, pp.673~678 (2021)
- GBD 2019 Diseases and Injuries Collaborators, "Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019", Lancet, 396, pp.1204~1222 (2020)
- Toyoshima O, "Endoscopic gastric atrophy is strongly associated with gastric cancer development after Helicobacter pylori eradication", Surg Endosc, 31, pp.2140~2148 (2017)
- Uemura N, "Helicobacter pylori infection and the development of gastric cancer", N Engl J Med, 345, pp.784~789 (2001)